Ignite Creation Date:
2025-12-24 @ 7:21 PM
Ignite Modification Date:
2026-02-03 @ 8:22 AM
Study NCT ID:
NCT04220203
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2025-06-26
First Post:
2020-01-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HER2-positive Breast Cancer | View |
Keywords: